People
Sam Isaly has finally stepped down from his position as a managing member OrbiMed more than four months after he was accused of sexual harassment. Sexual harassment allegations have been in the forefront of the news cycles for months as the #MeToo movement gained traction.
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
Casma Therapeutics closed on a Series A round totaling $58.5 million. The company was solely funded by Third Rock Ventures.
Despite raised awareness over the past few years, the gender diversity gap in the boardrooms of Fortune 1000 companies has remained at slightly less than 20 percent, as of 2017. There is evidence though that shows companies with more diversity at the highest levels see a higher return on investment overall.
A biohacker who injected himself with an alleged experimental herpes vaccine before a crowded conference earlier this year was found dead in a Washington, D.C. sensory deprivation tank and the conspiracy theorists are running wild.
Many of the trends that affect biopharma recruitment are trends that affect healthcare in general, as well as other industries.
Pfizer launched a new ad that celebrates diversity in its employment.
Allergan Chief Executive Officer Brent Saunders delivered a rosy review of the first quarter for 2018, including a 3 percent growth in revenue to $3.67 billion over the past three months. However, investors are not terribly pleased and shares have fallen nearly 4 percent this morning.
Eli Lilly and Company announced that Leena Gandhi will lead its immuno-oncology medical development program.
Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros. But Sanofi Genzyme sales were up 16.2 percent, mostly the result of its new immunology franchise.
PRESS RELEASES